ATE312105T1 - Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number: ATE312105T1
Authority: AT; Austria
Prior art keywords: hydroxy; lower alkyl; camptothecine; analogs; production
Prior art date: 1995-06-21

Application number

AT02077736T

Other languages

English (en)

Inventor

Dennis Bigg

Olivier Lavergne

Rodas Francesc Pla

Jacques Pommier

Gerard Ulibarri

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-21

Filing date

1996-06-21

Publication date

2005-12-15

1995-06-21 Priority claimed from GBGB9512670.2A external-priority patent/GB9512670D0/en

1996-06-21 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

2005-12-15 Application granted granted Critical

2005-12-15 Publication of ATE312105T1 publication Critical patent/ATE312105T1/de

Links

VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 5
125000003545 alkoxy group Chemical group 0.000 abstract 3
125000001475 halogen functional group Chemical group 0.000 abstract 3
150000001277 beta hydroxy acids Chemical class 0.000 abstract 2
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
229940127093 camptothecin Drugs 0.000 abstract 1
-1 camptothecin hydroxy lactone Chemical class 0.000 abstract 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
150000002596 lactones Chemical class 0.000 abstract 1
238000007142 ring opening reaction Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cephalosporin Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

AT02077736T 1995-06-21 1996-06-21 Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen ATE312105T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9512670.2A GB9512670D0 (en)	1995-06-21	1995-06-21	Camptothecin analogues
US61047696A	1996-03-04	1996-03-04

Publications (1)

Publication Number	Publication Date
ATE312105T1 true ATE312105T1 (de)	2005-12-15

Family

ID=26307258

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02077736T ATE312105T1 (de)	1995-06-21	1996-06-21	Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
AT96924010T ATE224900T1 (de)	1995-06-21	1996-06-21	Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendungals arzneimittel und diese enthaltende pharmazeutische zusammenfassungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT96924010T ATE224900T1 (de)	1995-06-21	1996-06-21	Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendungals arzneimittel und diese enthaltende pharmazeutische zusammenfassungen

Country Status (23)

Country	Link
EP (2)	EP1251125B1 (de)
JP (2)	JP3576171B2 (de)
KR (1)	KR100440838B1 (de)
CN (1)	CN1114608C (de)
AT (2)	ATE312105T1 (de)
AU (1)	AU716377B2 (de)
BR (1)	BR9608639A (de)
CA (1)	CA2225528C (de)
CL (1)	CL2004001168A1 (de)
CZ (1)	CZ296156B6 (de)
DE (2)	DE69635560T2 (de)
DK (2)	DK1251125T3 (de)
ES (2)	ES2184882T3 (de)
IL (2)	IL122635A (de)
MX (1)	MX9710228A (de)
NO (1)	NO316749B1 (de)
NZ (1)	NZ312715A (de)
PL (1)	PL185354B1 (de)
PT (1)	PT835258E (de)
RO (1)	RO117918B1 (de)
RU (1)	RU2164515C2 (de)
TW (1)	TW457234B (de)
WO (1)	WO1997000876A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2768431B1 (fr) *	1997-08-29	2000-03-24	Sod Conseils Rech Applic	Nouveaux analogues optiquement purs de la camptothecine, nouvel intermediaire de synthese optiquement pur et son procede de preparation
FR2790261B1 (fr) *	1999-02-26	2004-09-10	Sod Conseils Rech Applic	Nouveaux analogues optiquement purs de la camptothecine et leurs procedes de preparation
FR2757515B1 (fr) *	1996-12-20	2000-05-05	Sod Conseils Rech Applic	Formes prodrogues et nouveaux analogues de la camptothecine, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2757514B1 (fr) *	1996-12-20	1999-02-12	Sod Conseils Rech Applic	Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6559309B2 (en) *	1996-11-01	2003-05-06	Osi Pharmaceuticals, Inc.	Preparation of a camptothecin derivative by intramolecular cyclisation
UA57757C2 (uk) *	1996-12-20	2003-07-15	Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.)	Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
FR2772763B1 (fr) *	1997-12-24	2004-01-23	Sod Conseils Rech Applic	Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE19826499A1 (de) *	1998-06-13	1999-12-16	Beiersdorf Ag	Gegen Bakterien, Mycota, Viren, Parasiten und Protozoen wirksame Substanzen
US6207832B1 (en)	1999-04-09	2001-03-27	University Of Pittsburgh	Camptothecin analogs and methods of preparation thereof
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
MXPA02002032A (es) *	1999-08-27	2003-05-19	Ligand Pharm Inc	Compuestos moduladores del receptor de androgeno y metodos.
EP1212322A2 (de)	1999-08-27	2002-06-12	Ligand Pharmaceuticals Incorporated	8-substituierte-6-trifluoromethyl-9-pyrido[3,2-g]chiolinverbindungen als androgen rezeptormodulatoren
US6593493B1 (en)	1999-09-14	2003-07-15	Ligand Pharmaceuticals, Inc.	RXR modulators with improved pharmacologic profile
FR2801309B1 (fr) *	1999-11-18	2002-01-04	Adir	Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60124387T2 (de)	2000-02-28	2007-10-11	Pfizer Enterprises Sarl.	Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs
US6486320B2 (en)	2000-09-15	2002-11-26	Aventis Pharma S.A.	Preparation of camptothecin and of its derivatives
SK5122003A3 (en)	2000-10-27	2003-12-02	Aventis Pharma Sa	A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US6372906B1 (en)	2001-04-12	2002-04-16	University Of Pittsburgh	Synthesis of silyl camptothecins and silyl homocamptothecins
FR2825278A1 (fr) *	2001-05-30	2002-12-06	Sod Conseils Rech Applic	Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
US6723853B2 (en)	2001-08-27	2004-04-20	University Of Pittsburgh	Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins
AU2003225642A1 (en) *	2002-03-01	2003-09-16	Fluorous Techonologies Inc	Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs
ITRM20020305A1 (it) *	2002-05-31	2003-12-01	Sigma Tau Ind Farmaceuti	Camptotecine con anello lattonico modificato.
ITRM20030344A1 (it) *	2003-07-14	2005-01-15	Ist Naz Stud Cura Dei Tumori	7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
CN100408582C (zh) *	2004-02-12	2008-08-06	中国人民解放军第二军医大学	高喜树碱类化合物及其制备方法和用途
ITRM20040288A1 (it) *	2004-06-11	2004-09-11	Sigma Tau Ind Farmaceuti	Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
WO2006069344A2 (en)	2004-12-22	2006-06-29	Rutgers, The State University Of New Jersey	Controlled release hydrogels
CN100339377C (zh) *	2005-09-05	2007-09-26	合肥中科大生物技术有限公司	喜树碱衍生物及其制备
CN1319971C (zh) *	2005-09-09	2007-06-06	合肥中科大生物技术有限公司	喜树碱衍生物及其用途
CN100465175C (zh) *	2005-11-29	2009-03-04	中国人民解放军第二军医大学	7-位取代高喜树碱类化合物及作为药物的用途
CN1319970C (zh) *	2005-12-30	2007-06-06	合肥中科大生物技术有限公司	一种用作抗肿瘤剂的喜树碱衍生物及其制备方法
EP1998809B1 (de)	2006-03-30	2014-06-25	Drais Pharmaceuticals, Inc.	Konjugate von camptothecin und zelldurchdringenden peptiden und deren pharmazeutische zusammensetzungen.
WO2007123995A2 (en) *	2006-04-19	2007-11-01	Bionumerik Pharmaceuticals, Inc.	Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
CN101220037B (zh) *	2008-01-31	2011-02-16	中国人民解放军第二军医大学	10-位取代高喜树碱类化合物及其用途
CN100592871C (zh) *	2008-03-14	2010-03-03	浙江林学院	一种杀虫剂组合物及其加工方法
CN101979392A (zh) *	2010-09-26	2011-02-23	中国人民解放军第二军医大学	7-芳乙烯基取代高喜树碱类化合物及其作为药物的用途
US20140086975A1 (en)	2010-10-15	2014-03-27	Rutgers, The State University Of New Jersey	Hydrogel formulation for dermal and ocular delivery
CN102746314B (zh) *	2011-04-18	2016-07-06	华东师范大学	含有稳定7元内酯环的喜树碱类化合物、制备方法和用途
CN105601641B (zh) *	2015-12-22	2018-01-16	兰州大学	7‑位哌嗪磺酰胺喜树碱类化合物、制备方法及用途
CN106478648B (zh) *	2016-09-21	2018-11-06	桑迪亚医药技术（上海）有限责任公司	一种高喜树碱化合物及其合成方法
CN111777608B (zh) *	2020-07-08	2021-08-03	湖北精瑜材料有限公司	一种新型植物改性喹啉季铵盐化合物和制备方法及应用
AU2022216696A1 (en) *	2021-02-05	2023-08-17	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Camptothecin compound, preparation method therefor, and application thereof
CN117164601A (zh) *	2022-06-02	2023-12-05	华东师范大学	一种高喜树碱类小分子及其应用
KR20260089547A (ko) *	2023-10-10	2026-06-15	상하이 이노브콩 파마슈티컬 테크놀로지 코., 엘티디	새로운 i형 토포이소머라아제 억제제 및 그 제조 방법과 용도
CN120058721A (zh) *	2024-01-08	2025-05-30	杭州爱科瑞思生物医药有限公司	7-氟烷基取代的喜树碱衍生物的制备及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162532A (en) *	1990-12-20	1992-11-10	North Carolina State University	Intermediates and method of making camptothecin and camptothecin analogs
US5391745A (en) *	1992-07-23	1995-02-21	Sloan-Kettering Institute For Cancer Research	Methods of preparation of camptothecin analogs

1996
- 1996-06-21 DE DE69635560T patent/DE69635560T2/de not_active Expired - Lifetime
- 1996-06-21 AT AT02077736T patent/ATE312105T1/de not_active IP Right Cessation
- 1996-06-21 DK DK02077736T patent/DK1251125T3/da active
- 1996-06-21 KR KR1019970709577A patent/KR100440838B1/ko not_active Expired - Fee Related
- 1996-06-21 PL PL96324339A patent/PL185354B1/pl not_active IP Right Cessation
- 1996-06-21 PT PT96924010T patent/PT835258E/pt unknown
- 1996-06-21 MX MX9710228A patent/MX9710228A/es unknown
- 1996-06-21 RU RU98101135/04A patent/RU2164515C2/ru not_active IP Right Cessation
- 1996-06-21 AU AU64608/96A patent/AU716377B2/en not_active Ceased
- 1996-06-21 BR BR9608639A patent/BR9608639A/pt not_active IP Right Cessation
- 1996-06-21 IL IL12263596A patent/IL122635A/en not_active IP Right Cessation
- 1996-06-21 DK DK96924010T patent/DK0835258T3/da active
- 1996-06-21 CA CA002225528A patent/CA2225528C/fr not_active Expired - Fee Related
- 1996-06-21 DE DE69623961T patent/DE69623961T2/de not_active Expired - Lifetime
- 1996-06-21 RO RO97-02400A patent/RO117918B1/ro unknown
- 1996-06-21 EP EP02077736A patent/EP1251125B1/de not_active Expired - Lifetime
- 1996-06-21 AT AT96924010T patent/ATE224900T1/de not_active IP Right Cessation
- 1996-06-21 WO PCT/FR1996/000980 patent/WO1997000876A1/fr not_active Ceased
- 1996-06-21 CN CN96196127A patent/CN1114608C/zh not_active Expired - Fee Related
- 1996-06-21 ES ES96924010T patent/ES2184882T3/es not_active Expired - Lifetime
- 1996-06-21 JP JP50364497A patent/JP3576171B2/ja not_active Expired - Fee Related
- 1996-06-21 ES ES02077736T patent/ES2254600T3/es not_active Expired - Lifetime
- 1996-06-21 NZ NZ312715A patent/NZ312715A/xx not_active IP Right Cessation
- 1996-06-21 CZ CZ0415397A patent/CZ296156B6/cs not_active IP Right Cessation
- 1996-06-21 EP EP96924010A patent/EP0835258B1/de not_active Expired - Lifetime
- 1996-08-08 TW TW085109645A patent/TW457234B/zh not_active IP Right Cessation
1997
- 1997-12-19 NO NO19975988A patent/NO316749B1/no not_active IP Right Cessation
1999
- 1999-01-14 IL IL12804499A patent/IL128044A0/xx unknown
2003
- 2003-11-26 JP JP2003395824A patent/JP2004123756A/ja active Pending
2004
- 2004-05-20 CL CL200401168A patent/CL2004001168A1/es unknown

Also Published As

Publication number	Publication date
HK1056726A1 (en)	2004-02-27
EP1251125B1 (de)	2005-12-07
DE69623961D1 (de)	2002-10-31
JP3576171B2 (ja)	2004-10-13
ES2254600T3 (es)	2006-06-16
DE69623961T2 (de)	2003-05-08
DE69635560D1 (de)	2006-01-12
RO117918B1 (ro)	2002-09-30
BR9608639A (pt)	1999-06-29
PL185354B1 (pl)	2003-04-30
MX9710228A (es)	1998-03-31
HK1050686A1 (en)	2003-07-04
KR19990028263A (ko)	1999-04-15
DK0835258T3 (da)	2003-02-03
NO975988D0 (no)	1997-12-19
EP0835258A1 (de)	1998-04-15
CA2225528C (fr)	2007-06-05
NZ312715A (en)	2000-01-28
RU2164515C2 (ru)	2001-03-27
JPH11508249A (ja)	1999-07-21
IL122635A (en)	2001-10-31
PL324339A1 (en)	1998-05-25
IL122635A0 (en)	1998-08-16
IL128044A0 (en)	1999-11-30
EP1251125A3 (de)	2002-12-11
EP1251125A2 (de)	2002-10-23
EP0835258B1 (de)	2002-09-25
CA2225528A1 (fr)	1997-01-09
DE69635560T2 (de)	2006-08-17
AU716377B2 (en)	2000-02-24
CZ415397A3 (cs)	1998-08-12
KR100440838B1 (ko)	2004-12-17
NO975988L (no)	1998-02-19
TW457234B (en)	2001-10-01
HK1015783A1 (en)	1999-10-22
WO1997000876A1 (fr)	1997-01-09
PT835258E (pt)	2003-02-28
JP2004123756A (ja)	2004-04-22
CZ296156B6 (cs)	2006-01-11
CN1192740A (zh)	1998-09-09
DK1251125T3 (da)	2006-04-18
ATE224900T1 (de)	2002-10-15
ES2184882T3 (es)	2003-04-16
AU6460896A (en)	1997-01-22
NO316749B1 (no)	2004-04-26
CN1114608C (zh)	2003-07-16
CL2004001168A1 (es)	2005-05-20

Legal Events

Date

Code

Title

Description

2006-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1251125

Country of ref document: EP

2010-12-15

EEIH

Change in the person of patent owner

2012-03-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE224900T1 (de)	2002-10-15	Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendungals arzneimittel und diese enthaltende pharmazeutische zusammenfassungen
BR0013949A (pt)	2002-05-14	Prodroga de taxano, composição farmacêutica, e, método de tratamento de um paciente mamìfero
MA22344A1 (fr)	1992-07-01	Procede de preparation de nouveaux derives de l'erythromicine
BR0212458A (pt)	2004-10-19	Composto ou sal farmaceuticamente aceitável, ou um éster hidrolizável in vivo deste, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto ou sal farmaceuticamente aceitável, ou um éster hidrolizável in vivo deste, composição farmacêutica, e, processo para a preparação de um composto ou sais farmaceuticamente aceitável, ou ésteres hidrolizáveis in vivo deste
AU647481B2 (en)	1994-03-24	Hexahydroazepine derivatives, a process for their preparation and pharmaceutical compositions containing them
DE69319764D1 (de)	1998-08-27	Verfahren zur Herstellung von Beta-Lactamderivaten und Zwischenprodukt für ihre Synthese
DE68926981D1 (de)	1996-09-26	Cephemverbindungen und Verfahren zu ihrer Herstellung
BR0308018A (pt)	2005-01-04	Composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo, pró-droga, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hirolisável in vivo, composição farmacêutica, e, processo para a preparação de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo
AU4861693A (en)	1994-04-14	New chromene compounds having a triene side chain, process for the preparation thereof, and pharmaceutical compositions containing them
DE3769563D1 (de)	1991-05-29	Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
DE69720496D1 (en)	2003-05-08	Benzimidazolderivate
ES2130392T3 (es)	1999-07-01	Procedimiento para la preparacion de acido clavulanico.
ATE224393T1 (de)	2002-10-15	Verfahren zur herstellung von cephalosporinen und zwischenverbindungen in diesem verfahren
DE50211588D1 (de)	2008-03-13	Verfahren zur kontinuierlichen Herstellung von substituierten Oxazolen
AU678638B2 (en)	1997-06-05	Dibenzo(b,e)oxepine derivatives, process for producing them and medicaments containing them
DE50202096D1 (de)	2005-03-03	Verfahren zur Herstellung von 5-Alkoxy-Oxazolen sowie von Pyridoxinen
HUT68636A (en)	1995-07-28	Benzopyrane derivatives, process for producing them, and pharmaceutical compositions containing them
JPS5732286A (en)	1982-02-20	Novel antibiotic substance dk-7814
ATE116282T1 (de)	1995-01-15	Neue p-oxibenzoesäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.